These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19660029)

  • 1. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance.
    Radosevich M; Burnouf T
    Vox Sang; 2010 Jan; 98(1):12-28. PubMed ID: 19660029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety.
    Buchacher A; Iberer G
    Biotechnol J; 2006 Feb; 1(2):148-63. PubMed ID: 16892245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of intravenous immunoglobulin G (IVIG).
    Looney RJ; Huggins J
    Best Pract Res Clin Haematol; 2006; 19(1):3-25. PubMed ID: 16377538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation, purification and virus inactivation of intravenous immunoglobulin from human plasma.
    Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Banazadeh S
    Hum Antibodies; 2010; 19(1):1-6. PubMed ID: 20555125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of intravenous immunoglobulin G in autoimmune hematologic disorders.
    Blanchette VS; Kirby MA; Turner C
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):72-82. PubMed ID: 1509297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods used.
    Djoumerska I; Tchorbanov A; Pashov A; Vassilev T
    Scand J Immunol; 2005 Apr; 61(4):357-63. PubMed ID: 15853919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin replacement therapy in primary antibody deficiency diseases--maximizing success.
    Durandy A; Wahn V; Petteway S; Gelfand EW
    Int Arch Allergy Immunol; 2005 Mar; 136(3):217-29. PubMed ID: 15713984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
    Caballero S; Nieto S; Gajardo R; Jorquera JI
    Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic intravenous immunoglobulins.
    Lemieux R; Bazin R; Néron S
    Mol Immunol; 2005 May; 42(7):839-48. PubMed ID: 15829272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin treatment in autoimmune neurological disorders--effects on quality of life.
    Padua L; Sabatelli M; Evoli A; Pazzaglia C; Tonali P
    Hum Immunol; 2005 Apr; 66(4):417-21. PubMed ID: 15866706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intravenous immunoglobulin therapy].
    Mouthon L
    Rev Prat; 2005 May; 55(10):1049-56. PubMed ID: 16097244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigations of prion and virus safety of a new liquid IVIG product.
    Stucki M; Boschetti N; Schäfer W; Hostettler T; Käsermann F; Nowak T; Gröner A; Kempf C
    Biologicals; 2008 Jul; 36(4):239-47. PubMed ID: 18337119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Technology of immunoglobulin production. I. Technological aspects of purification].
    Volkov GL
    Ukr Biokhim Zh (1999); 2006; 78(3):88-98. PubMed ID: 17100315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment.
    Chang CE; Eo HG; Lee YS; Chung SK; Shin JS; Lah YK; Park CW; Jung JT; Huh JW; Lee SM
    Prep Biochem Biotechnol; 2000 Aug; 30(3):177-97. PubMed ID: 10919559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.
    Wasserman RL; Church JA; Peter HH; Sleasman JW; Melamed I; Stein MR; Bichler J;
    Eur J Pharm Sci; 2009 Jun; 37(3-4):272-8. PubMed ID: 19491015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin therapy: indications, potential side effects, and treatment guidelines.
    Suez D
    J Intraven Nurs; 1995; 18(4):178-90. PubMed ID: 7629638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders.
    Emmi L; Chiarini F
    Neurol Sci; 2002 Apr; 23 Suppl 1():S1-8. PubMed ID: 12032582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The viral safety of intravenous immune globulin.
    Yap PL
    Clin Exp Immunol; 1996 May; 104 Suppl 1():35-42. PubMed ID: 8625542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and immunological properties of four intravenous Immunoglobulin G preparations.
    Redwan EL
    Hum Antibodies; 2002; 11(3):79-84. PubMed ID: 12454368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of intravenous immunoglobulins in pediatrics].
    Duse M; Plebani A; Crispino P; Ugazio AG
    Pediatr Med Chir; 1991; 13(2):117-25. PubMed ID: 1896376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.